Oxford Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Oxford Asset Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-57,346	Closed	-$597K	–	2245
2019 Q3	$597K	Buy	+57,346	New	+$750K	0.01%	1192
2017 Q1	–	Sell	-40,298	Closed	-$431K	–	1521
2016 Q4	$431K	Buy	+40,298	New	+$487K	0.02%	612
2016 Q3	–	Sell	-90,956	Closed	-$616K	–	905
2016 Q2	$616K	Sell	90,956 -33,230	-27%	-$210K	0.02%	564
2016 Q1	$579K	Sell	124,186 -53,452	-30%	-$261K	0.02%	590
2015 Q4	$1.13M	Buy	+177,638	New	+$1.44M	0.03%	508

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Oxford Asset Management's STML Position: Q4 2019 in Review

Oxford Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 57,346 shares — an estimated $597K sold.

Oxford Asset Management first reported a position in STML in Q4 2015 and held it in 5 quarters. The position peaked at $1.13M in Q4 2015. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

Oxford Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 57,346 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $597K.
Oxford Asset Management first reported a position in Stemline Therapeutics, Inc. in Q4 2015 and held it in 5 quarters.
Oxford Asset Management's Stemline Therapeutics, Inc. position peaked at $1.13M in Q4 2015.
99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.